Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

165.00 -9.00 (-5.17%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio ↗

March 21, 2025

Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio.

Via Investor's Business Daily

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps ↗

March 21, 2025

Alnylam's Amvuttra receives FDA approval for ATTR-CM, expanding its use and securing broad insurance coverage as global regulatory reviews continue.

Via Benzinga

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

March 20, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews ↗

March 11, 2025

Via Benzinga

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

March 03, 2025

Via Benzinga

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Views ↗

February 11, 2025

Via Benzinga

How Do Investors Really Feel About Alnylam Pharmaceuticals? ↗

March 14, 2025

Via Benzinga

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

March 11, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

March 05, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years ↗

February 26, 2025

Via Benzinga

Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗

February 10, 2025

Via Benzinga

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

January 30, 2025

Via Benzinga

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

January 16, 2025

Via Benzinga

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

February 25, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 18, 2025

Via Benzinga

Alnylam Delivers a Big Q4 Earnings Beat ↗

February 13, 2025

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Via The Motley Fool

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

February 13, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

January 13, 2025

Via Benzinga

What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

January 13, 2025

Via Benzinga

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

January 30, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

January 12, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

How Is The Market Feeling About Alnylam Pharmaceuticals? ↗

December 24, 2024

Via Benzinga

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

December 09, 2024

Via Benzinga

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

January 06, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗

January 03, 2025

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Via Benzinga

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years ↗

January 03, 2025

Via Benzinga

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

November 27, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

November 25, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.